Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy

[Guest guest]

Vaccine. 2011 Apr 4. [Epub ahead of print]

Prevalence of protective level of hepatitis B antibody 3 years after

revaccination in HIV-infected children on antiretroviral therapy.

Lao-Araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisanthana T,

Sirisanthana V.

Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang

Mai, Thailand.

Abstract

After responding to highly active antiretroviral therapy (HAART), HIV-infected

children had a good response to hepatitis B immunization. However, there are

limited data on the durability of antibody to hepatitis B surface antigen

(anti-HBs) in these children. The primary objective of this study is to

determine the prevalence of protective anti-HBs level 3 years after a 3-dose HBV

revaccination among HIV-infected children with immune recovery (CD4 cell ™15%)

while on HAART. The secondary objective is to assess immunologic memory among

children who had waning of anti-HBs. An anti-HBs level of ™10mIU/mL was defined

as a protective antibody level. Sixty-nine HIV-infected children who had history

of a 3-dose HBV revaccination while receiving HAART were enrolled. The mean (SD)

of CD4 cell and duration of HAART at time of revaccination was 27.2% (6.7) and

5.9 years (0.4), respectively. The proportion of children with protective

anti-HBs level 3 years after the revaccination was 71.0% [95% CI, 58.8-81.3].

The geometric mean titer was 114(SD 5)IU/mL. By multivariate logistic analysis,

the predictors for protective anti-HBs level 3 years after revaccination were

CD4 cell count ™500cells/mm(3) at the time of vaccination (p=0.04) and anti-HBs

level ™100IU/mL at 1 month after completion of the 3-dose vaccination (p<0.001).

Anamnestic response after one booster dose was demonstrated among 14 of 17

children who had waning protective anti-HBs level (82.4% [95% CI, 62.2-102.6]).

Our findings support the recommendation of giving a 3-dose HBV vaccination to

HIV-infected children with immune recovery while receiving HAART.

Copyright ¿ 2011. Published by Elsevier Ltd.

PMID: 21473954 [PubMed - as supplied by publisher]

[Guest guest]

Vaccine. 2011 Apr 4. [Epub ahead of print]

Prevalence of protective level of hepatitis B antibody 3 years after

revaccination in HIV-infected children on antiretroviral therapy.

Lao-Araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisanthana T,

Sirisanthana V.

Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang

Mai, Thailand.

Abstract

After responding to highly active antiretroviral therapy (HAART), HIV-infected

children had a good response to hepatitis B immunization. However, there are

limited data on the durability of antibody to hepatitis B surface antigen

(anti-HBs) in these children. The primary objective of this study is to

determine the prevalence of protective anti-HBs level 3 years after a 3-dose HBV

revaccination among HIV-infected children with immune recovery (CD4 cell ™15%)

while on HAART. The secondary objective is to assess immunologic memory among

children who had waning of anti-HBs. An anti-HBs level of ™10mIU/mL was defined

as a protective antibody level. Sixty-nine HIV-infected children who had history

of a 3-dose HBV revaccination while receiving HAART were enrolled. The mean (SD)

of CD4 cell and duration of HAART at time of revaccination was 27.2% (6.7) and

5.9 years (0.4), respectively. The proportion of children with protective

anti-HBs level 3 years after the revaccination was 71.0% [95% CI, 58.8-81.3].

The geometric mean titer was 114(SD 5)IU/mL. By multivariate logistic analysis,

the predictors for protective anti-HBs level 3 years after revaccination were

CD4 cell count ™500cells/mm(3) at the time of vaccination (p=0.04) and anti-HBs

level ™100IU/mL at 1 month after completion of the 3-dose vaccination (p<0.001).

Anamnestic response after one booster dose was demonstrated among 14 of 17

children who had waning protective anti-HBs level (82.4% [95% CI, 62.2-102.6]).

Our findings support the recommendation of giving a 3-dose HBV vaccination to

HIV-infected children with immune recovery while receiving HAART.

Copyright ¿ 2011. Published by Elsevier Ltd.

PMID: 21473954 [PubMed - as supplied by publisher]